Digital Investment fuels AI-driven development of breakthrough genom... David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets.
News Roche's oral MS hope fenebrutinib hits the mark in phase 3 Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.